Envoyer la notice par courriel: A Randomized Phase II Study of Cabozantinib Versus Weekly Paclitaxel in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: an NRG Oncology/Gynecologic Oncology Group Study